Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.
Gorkin and Cheddar Consulting, 2600 Gullane Road, Powhatan V23139, USA.
Larry
L
Gorkin
Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard., Unit 0428, Houston, Texas 77030, USA and is a Nonresident Fellow in Health Policy at the Rice University's Baker Institute.
Hagop
H
Kantarjian
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016879:Salvage Therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate